Xenon (XENE) Insider Exercise and 10b5-1 Sale — 25,000 Shares
Rhea-AI Filing Summary
Xenon Pharmaceuticals insider transactions by Ian Mortimer show the reporting person exercised a fully vested option to buy 25,000 common shares at $7.69 and simultaneously sold 25,000 shares under a prearranged Rule 10b5-1 plan on 10/01/2025. The sale proceeds reflect an aggregate weighted-average price of $40.16 per share (individual sales ranged $40.00 to $40.495). After these transactions Mortimer directly beneficially owned 31,302 shares and indirectly owned 14,300 shares through his spouse, totaling 45,602 shares. The filing states the option exercised is fully vested and exercisable and that the sales were executed under a 10b5-1 plan.
Positive
- None.
Negative
- None.
Insights
TL;DR: Insider exercised low-strike options and sold a matching number of shares under a 10b5-1 plan, realizing material gains per share.
The reporting person exercised 25,000 options with a $7.69 strike and sold 25,000 shares at a weighted-average price of $40.16, implying a pre-tax spread of ~$32.47 per share on those exercised shares. This is a common liquidity action when options are deeply in-the-money and does not, by itself, indicate a change to company fundamentals. The use of a Rule 10b5-1 plan signals the sales were prearranged, which reduces immediate interpretive weight but remains material to holders because it changes insider ownership levels: direct holdings moved to 31,302 shares post-transaction.
TL;DR: Transactions are procedurally compliant; 10b5-1 plan use and full vesting are documented.
The Form 4 discloses the 10b5-1 sales plan adoption date and confirms the option was fully vested when exercised. Signatures include an attorney-in-fact, and the explanatory footnotes provide ranges and offer to supply detailed trade-level prices on request. From a governance perspective, disclosure appears complete and follows standards for insider reporting; no amendment or missing procedural detail is apparent within the filing text.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 25,000 | $0.00 | -- |
| Exercise | Common Shares | 25,000 | $7.69 | $192K |
| Sale | Common Shares | 25,000 | $40.16 | $1.00M |
| holding | Common Shares | -- | -- | -- |
Footnotes (1)
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2024. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $40.00 to $40.495, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. The shares subject to the option are fully vested and exercisable.
